• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    ELECTRICALLY HEATED AEROSOL DISTRIBUTION SYSTEM. The present invention relates to an aerosol dispensing system for dispensing aerosolized drug particles to a user, which comprises a cartridge and a device configured to receive the cartridge. The cartridge comprises: a first compartment comprising a source of distribution enhancing compound; a second compartment comprising a source of medication; a vaporizer to heat the medicine; and a transfer element for transmitting the medicine from the second compartment to the vaporizer. The cartridge may additionally comprise an aerosol forming chamber in fluid communication with the first compartment and the second compartment. The device comprises: an external housing; a source of energy; temperature control means for controlling the temperature of the first compartment of the cartridge; and electronic circuits configured to control power to the temperature control means from the power source. The electronic circuit is configured to keep the first cartridge compartment at a temperature between about 30 ° C and about 50 ° C. When in use, the drug reacts with the distribution enhancing compound in the gas phase to form aerosolized particles that contain (...).
    公开号:BR112015026971B1
    申请号:R112015026971-0
    申请日:2014-05-19
    公开日:2021-02-17
    发明作者:Michel THORENS；Olivier Cochand
    申请人:Philip Morris Products S.A.；
    IPC主号:
    专利说明:

    [0001] [001] The present invention relates to a cartridge for an aerosol dispensing system and a device configured to receive the cartridge. The invention also relates to an aerosol dispensing system for delivery to an aerosolized drug user, such as nicotine salt particles, which comprises a device and a cartridge, specifically for a smoking device for dispensing particles of aerosolized nicotine salt to a user. The invention further relates to a method of delivering an aerosolized drug, such as nicotine salt particles, to a user.
    [0002] [002] So-called "e-cigarettes" and other electrically operated smoking systems that vaporize a liquid nicotine formulation to form an aerosol that is inhaled by a user are known in the art. For example, WO 2009/132793 A1 describes an electrically heated smoking system comprising an enclosure and a replaceable nozzle in which the enclosure comprises an electrical power supply and electrical circuits. The nozzle consists of a liquid storage part, a capillary wick that has a first end that extends into the liquid storage part to come into contact with the liquid inside it and a heating element to heat a second end capillary wick. In use, the liquid is transferred from the liquid storage part towards the heating element by capillary action on the wick. The liquid at the second end of the wick is vaporized by the heating element. The liquid preferably includes a tobacco-containing material that comprises volatile tobacco-flavored compounds that are released from the liquid upon heating.
    [0003] [003] Commercially available e-cigarettes normally require significant energy to form an aerosol with a particle size suitable for distribution to a user.
    [0004] [004] WO 2008/121610 A1 and WO 2011/034723 A1 describe devices and methods for delivering nicotine and other drugs to an individual in which pyruvic acid is reacted with nicotine or other drugs in the gas phase to form an aerosol of salt particles nicotine pyruvate, or other medicine. At room temperature, pyruvic acid and nicotine are both volatile enough to form the respective vapors that react with each other in the gas phase to form nicotine pyruvate salt particles. However, pyruvic acid has a higher vapor pressure than nicotine at a given temperature. As a result, the efficiency of the gas phase reaction between pyruvic acid and nicotine is highly dependent on the ambient temperature, which can disadvantageously lead to an inconsistent distribution of nicotine to a user.
    [0005] [005] It would be desirable to provide an aerosol dispensing system that operates with reduced energy consumption compared to commercially available e-cigarettes. It would also be desirable to provide an aerosol delivery system that allows more consistent nicotine or other drug delivery per puff compared to known devices for delivering aerosolized nicotine to salt particles.
    [0006] [006] According to the invention, a cartridge is provided which comprises: a first compartment which comprises a source of volatile distribution enhancing compound; a second compartment comprising a source of medication; a vaporizer to heat the medicine; and a transfer element for transmitting the medicine from the second compartment to the vaporizer.
    [0007] [007] As will be discussed below, the use of cartridges according to the invention in an aerosol dispensing system advantageously allows for a more consistent drug delivery compared to known devices for dispensing salt particles. of nicotine, or other medication, aerosolized. That is to say, the drug delivery by drag during the use of cartridges according to the invention of an aerosol dispensing system is more consistent, than in known devices for the delivery of aerosolized nicotine, or medication, salt particles. In addition, the drug delivery by drag during the use of cartridges according to the invention of an aerosol dispensing system is more constant than in known devices for the delivery of aerosolized nicotine, or drug, salt particles.
    [0008] [008] As used herein, the term "volatile" refers to a distribution enhancing compound that has a vapor pressure of at least about 20 Pa. Unless otherwise stated, all vapor pressures referred to in this document they are vapor pressures at 25 ° C, measured according to ASTM E1194 - 07.
    [0009] [009] Preferably, the volatile distribution enhancing compound has a vapor pressure of at least about 50 Pa, more preferably at least about 75 Pa, most preferably at least 100 Pa at 25 ° C.
    [0010] [0010] Preferably, the volatile distribution enhancing compound has a vapor pressure less than or equal to about 400 Pa, more preferably less than or equal to about 300 Pa, even more preferably less than or equal to about 275 Pa, the more preferably less than or equal to about 250 Pa at 25 ° C.
    [0011] [0011] In certain embodiments, the volatile distribution enhancing compound may have a vapor pressure between about 20 Pa and about 400 Pa, more preferably between about 20 Pa and about 300 Pa, even more preferably between about 20 Pa and about 275 Pa, most preferably between about 20 Pa and about 250 Pa at 25 ° C.
    [0012] [0012] In other embodiments, the volatile distribution enhancing compound can have a vapor pressure between about 50 Pa and about 400 Pa, more preferably between about 50 Pa and about 300 Pa, and even more preferably between about 50 Pa and about 275 Pa, most preferably between about 50 Pa and about 250 Pa at 25 ° C.
    [0013] [0013] In other embodiments, the volatile distribution enhancing compound may have a vapor pressure between about 75 Pa and about 400 Pa, more preferably between about 75 Pa and about 300 Pa, even more preferably between about 75 Pa and about 275 Pa, most preferably between about 75 Pa and about 250 Pa at 25 ° C.
    [0014] [0014] In other additional embodiments, the volatile distribution enhancing compound may have a vapor pressure between about 100 Pa and about 400 Pa, more preferably between about 100 Pa and about 300 Pa, even more preferably between about 100 Pa and about 275 Pa, most preferably between about 100 Pa and 250 Pa at 25 ° C.
    [0015] [0015] The volatile distribution enhancing compound may comprise a single compound. Alternatively, the volatile distribution enhancing compound can comprise two or more different compounds.
    [0016] [0016] When the volatile distribution enhancing compound comprises two or more different compounds, the two or more different compounds combined have a vapor pressure of at least about 20 Pa at 25 ° C.
    [0017] [0017] Preferably, the distribution enhancing compound is a volatile liquid.
    [0018] [0018] The volatile distribution enhancing compound may comprise a mixture of two or more different liquid compounds.
    [0019] [0019] The volatile distribution enhancing compound may comprise an aqueous solution of one or more compounds. Alternatively, the volatile distribution enhancing compound may comprise a non-aqueous solution of one or more compounds.
    [0020] [0020] The volatile distribution enhancing compound may comprise two or more different volatile compounds. For example, the volatile distribution enhancing compound may comprise a mixture of two or more different volatile liquid compounds.
    [0021] [0021] Alternatively, the volatile distribution enhancing compound may comprise one or more non-volatile compounds and one or more volatile compounds. For example, the volatile distribution enhancing compound may comprise a solution of one or more non-volatile compounds in a volatile solvent or a mixture of one or more non-volatile liquid compounds and one or more volatile liquid compounds.
    [0022] [0022] In one embodiment, the volatile distribution enhancing compound comprises an acid. The volatile distribution enhancing compound can comprise an organic acid or an inorganic acid. Preferably, the volatile distribution enhancing compound comprises an organic acid, more preferably a carboxylic acid, most preferably an alpha-keto or 2-oxo acid.
    [0023] [0023] In a preferred embodiment, the volatile distribution enhancing compound in the first compartment comprises an acid selected from the group consisting of 3-methyl-2-oxovaleric acid, pyruvic acid, 2-oxovaleric acid, 4-methyl-2 acid -oxovaleric, 3-methyl-2-oxobutanoic acid, 2-oxo-octanoic acid and combinations thereof. In a particularly preferred embodiment, the first compartment comprises pyruvic acid.
    [0024] [0024] In one embodiment, the volatile distribution enhancing compound comprises ammonium chloride.
    [0025] [0025] In a preferred embodiment, the source of the volatile distribution enhancement compound comprises a sorption element and a volatile distribution enhancement compound sorbed onto the sorption element.
    [0026] [0026] As used herein, "sorbed" means that the volatile distribution enhancing compound is adsorbed on the surface of the sorption element, or absorbed on the sorption element, or adsorbed on and absorbed on the sorption element. Preferably, the volatile distribution enhancing compound is adsorbed onto the sorption element.
    [0027] [0027] The sorption element can be formed from any suitable material or combination of materials. For example, the sorption element may comprise one or more of glass, stainless steel, aluminum, polyethylene (PE), polypropylene, polyethylene terephthalate (PET), polybutylene terephthalate (PBT), polytetrafluoroethylene (PTFE), expanded polytetrafluoroethylene (ePTFE ) and BAREX®.
    [0028] [0028] In a preferred embodiment, the sorption element is a porous sorption element.
    [0029] [0029] For example, the sorption element may be a porous sorption element comprising one or more materials selected from the group consisting of porous plastic materials, porous polymeric fibers and porous glass fibers.
    [0030] [0030] The sorption element is preferably chemically inert with respect to the volatile distribution enhancing compound.
    [0031] [0031] The sorption element can be of any suitable size and shape.
    [0032] [0032] In a preferred embodiment, the sorption element is a substantially cylindrical plug. In a particularly preferred embodiment, the sorption element is a substantially cylindrical porous plug.
    [0033] [0033] In another preferred embodiment, the sorption element is a substantially cylindrical hollow tube. In another particularly preferred embodiment, the sorption element is a substantially cylindrical, hollow porous tube.
    [0034] [0034] The size, shape and composition of the sorption element can be chosen to allow a desired amount of the volatile distribution enhancing compound to be sipped on the sorption element.
    [0035] [0035] In a preferred embodiment, between about 20 µl and about 200 µl, more preferably between about 40 µl and about 150 µl, most preferably between about 50 µl and about 100 µl of the breeding compound volatile distribution are sipped on the sorption element.
    [0036] [0036] The sorption element acts advantageously as a reservoir for the volatile distribution enhancing compound.
    [0037] [0037] The adsorption element can be configured to transmit the volatile distribution enhancement compound from the inside of the first compartment to the air drawn through the cartridge. For example, the adsorption element may comprise capillary material for the transmission of the volatile distribution improvement compound from the first compartment to the air drawn through the cartridge by means of capillary action. In certain embodiments, the adsorption element may comprise a capillary wick for transmitting the volatile distribution improvement compound from the first compartment to the air swallowed through the cartridge by means of capillary action.
    [0038] [0038] The use of a volatile distribution enhancing compound advantageously allows aerosol dispensing systems comprising cartridges according to the invention to operate with reduced energy consumption compared to commercially available e-cigarettes. The energy consumption of the aerosol dispensing system can be reduced by reducing the energy required to vaporize the drug due to the fact that the volatile distribution enhancing compound increases the rate of drug delivery to a user. In contrast, in commercially available e-cigarettes, in order to increase the rate of nicotine distribution to a user, additional energy is needed to vaporize the nicotine formulation to generate smaller aerosol particles. By reducing the energy required to generate aerosol suitable for dispensing to a user, the operating temperature of aerosol dispensing systems comprising cartridges according to the invention can also be advantageously reduced.
    [0039] [0039] In this way, the invention allows a cost-effective, compact and easy-to-use aerosol dispensing system to be provided. In addition, by using an acid or ammonium chloride as the distribution enhancing compound in cartridges according to the invention, the pharmacokinetic rate of the drug as compared to commercially available e-cigarettes can be advantageously increased.
    [0040] [0040] In a preferred embodiment, the cartridge also comprises an aerosol forming chamber in fluid communication with compartment for the first and the second compartment. In use, the drug reacts with the volatile distribution enhancing compound in the gas phase in the aerosol forming chamber to form particles containing aerosolized drug.
    [0041] [0041] Preferably, the cartridge additionally comprises at least one air inlet upstream of the first compartment, and at least one air inlet downstream of the aerosol forming chamber, the at least one air inlet and at least one air outlets arranged to define an air flow path that extends from at least one air inlet to at least one air outlet through the first compartment, the vaporizer and the aerosol forming chamber.
    [0042] [0042] As used herein, the terms "upstream" and "downstream" are used to describe the relative positions of components, or portions of components, of cartridges, aerosol dispensing devices and aerosol dispensing systems of according to the invention in relation to the direction of the air drawn through the cartridges, aerosol dispensing devices and aerosol dispensing systems when using the same.
    [0043] [0043] As used in this document, the term "air inlet" is used to describe one or more openings through which air can be drawn into the cartridge.
    [0044] [0044] As used in this document, the term "air outlet" is used to describe one or more openings through which air can be drawn out of the cartridge.
    [0045] [0045] In a preferred embodiment, the at least one air inlet comprises a µlurality of perforations provided in an external cartridge housing. Preferably, the perforations extend circumferentially around the outer housing.
    [0046] [0046] Preferably, the drug has a melting point below 150 degrees Celsius.
    [0047] [0047] Alternatively, or in addition to this, the medicine preferably has a boiling point below 300 degrees Celsius.
    [0048] [0048] In certain preferred embodiments, the drug comprises one or more aliphatic or aromatic, saturated or unsaturated nitrogen bases (alkaline compounds comprising nitrogen) in which the nitrogen atom is present in a heterocyclic ring or in an acyclic chain ( replacement).
    [0049] [0049] The drug may comprise one or more compounds selected from a group consisting of: nicotine; 7- Hydroxytraginine; Arecoline; Atropine; Bupropion; Catina (D-norpseudoephedrine); Chloropheneramine; Dibucaine; Dimemorfan, Dime-tiltriptamina, Diphenhydramine, Ephedrine, Hordenine, Hyoscyamine, Isoare-choline, Levorfanol, Lobelina, Mesembrina, Mitraginina, Muscatina, Pro-caína, Pseudoephedrine, Pyrilamine, Racloprida, Ritodrina, Escopolami-e ; constituents of tobacco smoke, such as Tetrahydroisoquinolines 1,2,3,4, Anabasin, Anata-bina, Cotinine, Myosmin, Nicotine, Norcotinin and Nornicotine; anti-asthmatic drugs, such as Orciprenaline, Propranolol and Terbutaline; anti-angina drugs, such as Nicorandil, Oxprenolol and Verapamil; anti-arrhythmia drugs, such as Lidocaine; nicotinic agonists, such as Epi-batidine, 5- (2R) -azetidinylmethoxy) -2-chloropyridine (ABT-594), (S) -3-methyl-5- (1-methyl-2-pyrolidinyl) isoxazole (ABT 418) and (±) -2- (3-Pyridinyl) -1-azabicyclo [2.2.2] octane (RJR-2429); nicotinic antagonists, such as Methylicacotinin and Mecamylamine; acetyl cholinesterase inhibitors, such as Galantamine, Pyridostigmine, Fisostigmine and Tacrine; and MAO inhibitors, such as Methoxy-N, N-dimethyltryptamine, 5-methoxy-a-methyltryptamine, Alpha-methyltryptamine, Iproclozide, Iproniazide, Isocarbon-xazide, Linezolid, Meclobemide, N, N - Dimethyltryptamine, Phenylzine, Phenylzine, Phenylzine, Phenylzine, Phenylzine, Phenylzine, Phenylzine , Toloxatone, Tranylcypromine and Tryptamine.
    [0050] [0050] The source of medication is preferably a source of nicotine.
    [0051] [0051] The medicament source may comprise a sorption element and a sorbent medicine in the sorption element.
    [0052] [0052] The second compartment can comprise a sorption element with a medicine sorbed on it. More preferably, the second compartment comprises a porous sorption element with the drug sorbed thereon. The porous sorption element may comprise one or more porous materials selected from the group consisting of porous µlastic materials, porous polymeric fibers and porous glass fibers. The one or more porous materials may or may not be capillarity materials and are preferably inert to ammonium acid or chloride. The specific preferred porous material or materials will depend on the properties of the drug. The one or more porous materials can have any suitable porosity, in order to be used with different medicaments with different physical properties.
    [0053] [0053] Inclusion of a sorption element with a medicine absorbed on it in the second compartment can advantageously reduce the risk of leakage of the medicine from the cartridge.
    [0054] [0054] In addition, by choosing a sorption element with suitable properties, the inclusion of a sorption element can allow for improved control of drug release.
    [0055] [0055] In preferred embodiments, the first cartridge compartment comprises a source of volatile distribution enhancing compound and the second cartridge compartment comprises a source of nicotine. The nicotine source may comprise one or more of nicotine, nicotine base, a nicotine salt, such as nicotine-HCl, nicotine bitartrate, or nicotine ditartrate, or a nicotine derivative.
    [0056] [0056] The nicotine source may comprise natural nicotine or synthetic nicotine.
    [0057] [0057] The nicotine source may comprise pure nicotine, a solution of nicotine in an aqueous or non-aqueous solvent, or a liquid tobacco extract.
    [0058] [0058] The nicotine source may further comprise an electrolyte-forming compound. The electrolyte-forming compound can be selected from the group consisting of alkali metal hydroxides, alkali metal oxides, alkali metal salts, alkaline earth metal oxides, alkaline earth metal hydroxides and combinations thereof.
    [0059] [0059] For example, the nicotine source may comprise an electrolyte-forming compound selected from the group consisting of potassium hydroxide, sodium hydroxide, lithium oxide, barium oxide, potassium chloride, sodium chloride, carbonate sodium, sodium citrate, ammonium sulfate and combinations thereof.
    [0060] [0060] In certain embodiments, the nicotine source may comprise an aqueous solution of nicotine, nicotine base, a nicotine salt or a nicotine derivative and an electrolyte-forming compound.
    [0061] [0061] Alternatively, or in addition to this, the nicotine source may additionally comprise other components including, but not limited to, natural flavors, artificial flavors and anti-oxidants. Preferably, the second compartment comprises a source of liquid medication. Preferably, the second compartment is configured to contain between about 50 microliters and about 150 microliters of the liquid medicine, more preferably about 100 microliters of the liquid medicine.
    [0062] [0062] The liquid medicine has a boiling point suitable for use in an aerosol dispensing system as described in this document: if the boiling point is too high, the vaporizer will not be able to vaporize the liquid medicine. The liquid medicine also has physical properties that allow the medicine to be transmitted via the transfer element from the second compartment to the vaporizer. Preferably, the liquid medicine has physical properties, including viscosity, which allow the liquid medicine to be transmitted through the transfer element from the second compartment to the vaporizer by means of capillary action.
    [0063] [0063] The vaporizer is preferably located downstream of the first compartment in such a way that the air drawn through the cartridge passes through the first compartment before passing through the vaporizer.
    [0064] [0064] The vaporizer preferably comprises an electrically driven heater, the heater being connectable to an electricity supply. The heater preferably comprises at least one heating element configured to heat the medicament so as to form a vapor containing medicament. The heater may comprise a single heating element. Alternatively, the heater may comprise more than one heating element, for example two, or three, or four, or five, or six or more heating elements. The heating element or heating elements can be arranged properly in order to vaporize the medicine as effectively as possible. The cartridge preferably comprises electrical contacts configured to be coupled to a power source in an aerosol dispensing device to supply power to at least one heating element.
    [0065] [0065] The at least one heating element preferably comprises a material with electrical resistance. Suitable electrically resistant materials include, but are not limited to: semiconductors such as doped ceramics, electrically "conductive" ceramics (such as, for example, molybdenum disilicate), carbon, graphite, metals, metal alloys and composite materials made from from a ceramic material and a metallic material. Such composite materials may comprise doped or non-doped ceramics. Examples of suitable doped ceramics include doped silicon carbides. Examples of suitable metals include titanium, zirconium, tantalum and metals of the µlatin group. Examples of suitable metal alloys include stainless steel, alloys containing nickel, cobalt, chromium, aluminum, titanium, zirconium, hafnium, niobium, molybdenum, tantalum, tungsten, tin, gallium, manganese and iron, and nickel, iron, superalloys. cobalt, stainless steel, timetal and alloys based on iron, manganese and aluminum. In composite materials, the material with electrical resistance can optionally be immersed in, encapsulated in or coated with an insulated material or vice versa, depending on the energy transfer kinetics and the required external physiochemical properties. Examples of suitable composite heating elements are disclosed in US 5,498,855, WO 03/095688 A2 and US 5,514,630.
    [0066] [0066] The at least one heating element can take any suitable shape. For example, the at least one heating element can take the form of a heating pad, such as those described in US 5,388,594, US 5,591,368 and US 5,505,214. Alternatively, the at least one heating element can take the form of a coating or substrate with different electrically conductive portions, as described in EP 1 128 741 A1, or a metal tube with electrical resistance, as described in WO 2007/066374 A1. Alternatively, the at least one heating element may be a disk end heater or a combination of a disk heater with heating needles or rods. Alternatively, the at least one heating element can take the form of an etched metal sheet isolated between two layers of an inert material. In such embodiments, the inert material may comprise Kapton®, pure polyimide or mica sheet. Alternatively, the at least one heating element can take the form of a sheet of material that can be wrapped around the vaporizer. The sheet can be made from any suitable material, for example, an aluminum-based alloy, an aluminum-manganese-iron based alloy or Timetal. The sheet may have a rectangular shape, or it may have a standardized shape that can form a coil-like structure when wrapped around the vaporizer. Other alternatives include a heating wire or filament, for example, a nickel-chromium (Ni-Cr) wire, µlatin, tungsten or steel alloy, such as those described in EP 1 736 065 A1, or a heating wire .
    [0067] [0067] In a preferred embodiment, the at least one heating element comprises a coil of wire surrounding the vaporizer. In this embodiment, the thread is preferably a metallic thread. Most preferably, the wire is a metal alloy wire. The heating element can partially or completely surround the vaporizer.
    [0068] [0068] In an alternative embodiment, the vaporizer may comprise an atomizer including at least one heating element. In addition to the heating element, the atomizer can include one or more electromechanical elements, such as piezoelectric elements. In addition or, alternatively, the atomizer can also include elements that use electrostatic, electromagnetic or pneumatic effects.
    [0069] [0069] The transfer element may comprise a porous material. The transfer element may have a first portion, which extends inside the second compartment, and a second portion adjacent to the vaporizer.
    [0070] [0070] Preferably, the transfer element comprises a capillarity material to transmit the medicament from the second compartment to the vaporizer by means of capillary action. The capillary material can be a capillary wick with a first portion, which extends inside the second compartment, and a second portion adjacent to the vaporizer. In use, the medicine is transferred from the second compartment to the vaporizer by means of capillary action on the capillary wick. When the vaporizer is activated, the medicine in the second portion of the capillary wick is vaporized to form a medicine-containing vapor.
    [0071] [0071] Preferably, the vaporizer is configured to heat the medicine in the second portion of the capillary wick to a temperature between about 60 ° C and about 150 ° C. Most preferably, the vaporizer is configured to heat the medicine in the second portion of the capillary wick to a temperature between about 65 ° C and about 120 ° C. Even more preferably, the vaporizer is configured to heat the medicine in the second portion of the capillary wick to a temperature between about 70 ° C and about 100 ° C to form a vapor containing the medicine.
    [0072] The capillary wick may be a linear capillary wick with a first free end extending into the second compartment and a second free end adjacent to the vaporizer. Alternatively, the capillary wick can be a tortuous capillary wick. In such embodiments, the first portion of the capillary wick extending into the interior of the vaporizer and the second portion of the capillary wick adjacent to the vaporizer may be free ends of the capillary wick or tortuous portions of the capillary wick. For example, the capillary wick may be a U-shaped capillary wick in which the curved portion of the U-shaped capillary wick extends into the interior of the second compartment and the free ends of the U-shaped capillary wick are adjacent to the vaporizer. Alternatively, the capillary wick can be a U-shaped capillary wick in which the free ends of the U-shaped capillary wick extend into the interior of the second compartment and the curved portion of the U-shaped capillary wick is adjacent to the vaporizer . It should be understood that any other capillary wick format can also be used.
    [0073] [0073] The capillary wick can have a fibrous or spongy structure. For example, the capillary wick may comprise a µlurality of fibers or threads, generally aligned in the longitudinal direction of the cartridge or spongy material formed in the form of a rod, along the longitudinal direction of the cartridge. The structure of the wick forms a µlurality of holes or small tubes, through which the medicine can be transported from the second compartment to the vaporizer, by means of capillary action. The capillary wick can comprise any suitable material or combination of suitable materials. Examples of suitable materials are ceramic or graphite based materials in the form of fibers or sintered powders. The capillary wick can have any capillarity and porosity suitable for use with drugs that have different physical properties, such as density, viscosity, surface tension and vapor pressure.
    [0074] [0074] A porous material can be provided between the capillary wick and the vaporizer. The porous material can be of any suitable material that is permeable to the drug and allows it to migrate from the capillary wick to the vaporizer. The porous material is preferably inert in relation to the medicament. The porous material may or may not be a capillarity material. The porous material can comprise a hydrophilic material to improve the distribution and spread of the medicament. This can assist in the consistent formation of steam. The specific preferred porous material or materials will depend on the physical properties of the drug. The porous material can have any porosity suitable for use with drugs with different physical properties. Preferably, the capillary wick and the porous material are in contact, since this gives rise to a good transfer of the medicine.
    [0075] [0075] The at least one heating element can heat the medicine at the second end of the capillary wick by means of conduction. The heating element can be at least partially in contact with the second end of the capillary wick. Alternatively, the heat from the heating element can be conveyed to the medicine at the second end of the capillary wick by means of a heat conducting element. Alternatively, the at least one heating element can transfer heat to the ambient air swallowed through the cartridge during use, which in turn heats the medication at the second end of the capillary wick by means of convection. The ambient air can be heated before passing through the second end of the capillary wick. Alternatively, the ambient air can be drawn in over the second end of the wick and then heated, as described in WO 2007/078273 A1.
    [0076] [0076] The first compartment comprising the volatile distribution enhancing compound can be supplied circumferentially around at least a portion of the second compartment. In such embodiments, the first compartment can be defined by an external wall of the second compartment and an external cartridge housing. Alternatively, the first compartment and the second compartment can be arranged sequentially along the longitudinal direction of the cartridge with the first compartment upstream of the second compartment. In such embodiments, the first compartment and the second compartment can abut each other or can be spaced along the longitudinal direction of the cartridge.
    [0077] [0077] Preferably, the first compartment is substantially sealed before the first use of the cartridge. For example, the first compartment may comprise one or more seals that can be punctured, or otherwise opened when first using the cartridge.
    [0078] [0078] As described above, the volatile distribution enhancing compound interacts with the drug in the gas phase to form drug containing particles. Where the volatile distribution enhancing compound is an acid, and the drug source is a source of nicotine, the acid interacts with nicotine in the gas phase to form nicotine salt particles. Preferably, the mass median aerodynamic diameter of the nicotine salt particles is less than about 6 microns. The mass median aerodynamic diameter of the nicotine salt particles can be less than about 1 micron. Preferably, the mass median aerodynamic diameter of the nicotine salt particles is between 0.5 microns and about 5 microns.
    [0079] [0079] The cartridge may additionally comprise a third compartment. Preferably, the third compartment is located downstream of the second compartment. If the cartridge comprises an aerosol-forming chamber, the third compartment is preferably located downstream of the aerosol-forming chamber. The third compartment can comprise an aroma source. Alternatively, or in addition, the third component may include a filter material capable of removing at least a portion of any unreacted volatile distribution enhancing compound mixed with particles containing aerosolized drug swallowed through the third compartment. The filter material can include an adsorbent, such as activated carbon. As will be appreciated, any number of additional compartments can be provided as desired. For example, the cartridge can include a third compartment, comprising a filter material and a fourth filter compartment downstream of the third compartment composed of a flavor source.
    [0080] [0080] Preferably, the cartridge comprises an opaque external housing. This advantageously reduces the risk of degradation of the volatile distribution enhancing compound and the drug due to exposure to light.
    [0081] [0081] In accordance with a further aspect of the invention, a device configured to receive a cartridge as described in this document is provided. The device comprises: an external housing; a source of energy; temperature control means for controlling the temperature of the first compartment of the cartridge; and electronic circuits configured to control energy for the means of controlling the power source; wherein the electronic circuit is configured to maintain the first cartridge compartment at a temperature between about 30 ° C and about 50 ° C.
    [0082] [0082] In a preferred embodiment, the control means comprise a heater to heat the first compartment of the cartridge.
    [0083] [0083] The use of such a device in combination with a cartridge according to the invention, advantageously allows more consistent distribution of generation and aerosol medicine per drag. By configuring the device to maintain the first cartridge compartment at a temperature between about 30 ° C and 50 ° C, the effect of environmental conditions at the time of generation and aerosol drug delivery per drag can be mitigated.
    [0084] [0084] Alternatively, or in addition to this, the device may comprise a heater to heat the ambient air drawn through the device to a temperature between about 30 ° C and about 50 ° C before passing through the first cartridge compartment .
    [0085] [0085] In accordance with a further aspect of the invention, an aerosol dispensing system is provided. The aerosol delivery system comprises: a device as described in this document in cooperation with a cartridge as described in this document. The device or cartridge comprises a first compartment which comprises a volatile distribution enhancing compound. The device or cartridge comprises a second compartment which comprises a source of medication. The device or cartridge comprises a vaporizer to heat the medicine. The device or cartridge additionally comprises a transfer element for transmitting the medicament from the second compartment to the vaporizer. The device or cartridge further comprises an aerosol-forming chamber in fluid communication with the first compartment and the second compartment. In use, the drug reacts with the volatile distribution enhancing compound in the gas phase in the aerosol forming chamber to form particles containing aerosolized drug.
    [0086] [0086] Preferably, the device or the cartridge additionally comprise a nozzle in fluid communication with the aerosol forming chamber. Preferably, the nozzle is part of the cartridge.
    [0087] [0087] The nozzle can comprise any suitable material or a combination of suitable materials. Examples of suitable materials include thermoplastics that are suitable for food or pharmaceutical applications, for example, polypropylene, polyether tertone (PEEK) and polyethylene.
    [0088] [0088] Preferably, the cartridge is not refillable. In this way, when the medicine in the second compartment of the cartridge has been consumed entirely, the cartridge is replaced.
    [0089] [0089] In certain embodiments, the device, as well as the cartridge, can be disposable.
    [0090] [0090] Advantageously, all elements of the device potentially in contact with the volatile distribution enhancing compound or the drug are changed when the cartridge is replaced. This avoids any kind of cross contamination in the device between different nozzles and different cartridges, for example, cartridges that comprise different volatile distribution enhancing compounds or medications.
    [0091] [0091] The medication in the second compartment can be advantageously protected from exposure to oxygen (because oxygen cannot generally enter the second compartment through the capillary wick or other transfer element) and, in some modalities, to light, from so that the risk of drug degradation is significantly reduced. Therefore, a high level of hygiene can be maintained. In addition, the risk of the vaporizer becoming clogged with the drug can be significantly reduced, advantageously, by replacing the cartridge at appropriate intervals.
    [0092] [0092] In preferred modes, the vaporizer comprises an electrically driven heater, the heater being connectable to the power source in the device. When the device and the cartridge are coupled, the heater in the cartridge is in electrical connection with the power supply through the circuits, the circuits being arranged in order to supply energy to the heater in the cartridge. In one embodiment, power is supplied to the heater in the cartridge when the user activates a switch. In this mode, the heater in the cartridge is supplied with substantially continuous energy for a fixed period of time. Preferably, the energy source has enough energy to power the heater in the cartridge for at least about 4 minutes, preferably at least about 5 minutes, and more preferably about 6 minutes. It has been found that the average duration of a smoking experiment is approximately 6 minutes.
    [0093] [0093] Preferably, the energy source comprises enough energy to allow the user to start between about 200 puffs and about 500 puffs.
    [0094] [0094] In an alternative mode, energy is supplied to the heater in the cartridge only when a user initiates a drag. Preferably, the electrical circuit comprises a sensor to detect the air flow, indicative of a user starting a drag. The sensor can be an electromechanical device. Alternatively, the sensor can be any one of: a mechanical device, an optical device, an opto-mechanical device, a sensor based on microelectric mechanical systems (MEMS). In such embodiments, electronic circuits are preferably arranged to provide a pulse of electrical current to the heater in the cartridge when the sensor detects a user starting a drag. Preferably, the time period of the electric current pulse is predetermined, depending on the amount of nicotine formulation that is to be vaporized. The electronic circuit is preferably programmable for this purpose.
    [0095] [0095] Alternatively, electronic circuits may comprise a switch operable manually by a user to initiate a drag. In such modalities, the time period of the pulse of electric current sent to the heater in the cartridge by manual operation of the commutator by a user is preferably pre-configured, depending on the amount of nicotine formulation to be vaporized. The electronic circuit is preferably programmable for this purpose.
    [0096] [0096] Preferably, the power source comprises a battery contained in the device. The energy source can be a lithium-ion battery or a variety thereof, for example a polymeric lithium-ion battery. Alternatively, the energy source can be provided by a nickel-metal hydride battery or a nickel-cadmium battery or a fuel cell.
    [0097] [0097] The power source may comprise circuits chargeable by means of an external charging portion. In this case, the circuit, when charged, preferably supplies energy for a predetermined number of drag, after which the circuit must be reconnected to the external loading portion. An example of an appropriate circuit comprises one or more capacitors or rechargeable batteries.
    [0098] [0098] Preferably, the device and the cartridge are arranged so as to lock into each other in a release way when coupled.
    [0099] [0099] The external housing of the device can be formed from any suitable material or combination of suitable materials. Examples of suitable materials include, but are not limited to, metals, alloys, µlastics or composite materials containing one or more of these materials. Preferably, the outer housing is light and not brittle.
    [0100] [00100] The aerosol dispensing system and the device are preferably portable. The aerosol dispensing system can be of a size and shape comparable to a conventional smoking article, such as a cigar or cigarette.
    [0101] [00101] In accordance with a further aspect of the invention, a method of dispensing aerosolized particles containing medication to a user is provided. The method comprises: controlling the temperature of a volatile distribution improving compound between about 30 ° C and about 50 ° C to form a vapor containing a volatile distribution improving compound; heating a medicine source to a temperature between about 70 ° C and about 100 ° C to form a vapor containing the medicine; and contacting the vapor containing the volatile distribution enhancing compound with the vapor containing the drug, so as to form aerosolized particles containing particles.
    [0102] [00102] In a preferred embodiment, the step of controlling the temperature of the distribution improving compound may include heating the distribution improving compound.
    [0103] [00103] As will be appreciated, several factors influence the formation of particles containing medicines. In general, in order to control the distribution of the drug, it is important to control the vaporization of the drug and the distribution of the volatile distribution enhancing compound. It is also important to control the relative quantities of the drug and the volatile distribution enhancing compound. In the preferred embodiment, where the volatile distribution enhancing compound is an acid and the source of medication is a source of nicotine, the molar ratio of acid to nicotine in the aerosol-forming chamber is about 1: 1. It has been found that the use of acid or ammonium chloride as a distribution-enhancing compound increases the rate of nicotine distribution to a user by approximately double for equivalent energy supplied to the vaporizer.
    [0104] [00104] The vaporization of the volatile distribution enhancement compound is controlled by the concentration of the volatile distribution enhancement compound in the first compartment, and by the external exchange area of the volatile distribution enhancement compound in the first compartment. The vaporization of the volatile distribution enhancing compound can be controlled by heating the first compartment of the cartridge or by heating the ambient air drawn through the device before it passes through the first compartment of the cartridge. In preferred embodiments in which the first compartment comprises pyruvic acid, preferably about 60 micrograms of pyruvic acid are vaporized by drag.
    [0105] [00105] The vaporization of the medicine can be controlled by means of the energy supplied to the vaporizer and through the properties of the transfer element to transmit the medicine to the vaporizer.
    [0106] [00106] Preferably, in which the source of medication is a source of nicotine, the energy supplied to the vaporizer is between about 0.1 W and about 0.2 W to produce an ideal nicotine distribution for the user of about 100 micrograms per puff. More preferably, the energy supplied to the heater is between about 0.13 W and about 0.14 W.
    [0107] [00107] In commercial e-cigarettes, the energy supplied to the vaporizer is, in most cases, much greater; in some cases the measurements show a power supply between 3.7 W and about 5 W. The reduction in energy consumption in aerosol dispensing systems and devices according to the invention in comparison to such e-cigarettes is therefore , remarkable. In addition, the operating temperature of the vaporizer in aerosol dispensing systems and cartridges according to the invention can be reduced to between about 80 ° C to about 100 ° C, compared to about 200 ° C to about 300 ° C in commercial e-cigarettes.
    [0108] [00108] For the avoidance of doubt, the features described above in relation to one aspect of the invention may also be applicable to other aspects of the invention. In particular, the characteristics described above with respect to cartridges, devices and aerosol dispensing systems according to the invention can also refer, where appropriate, to methods according to the invention, and vice versa.
    [0109] [00109] An exemplary embodiment of the invention will now be described, with reference to the accompanying drawings in which:
    [0110] [00110] Figures 1 (a) - (d) show an aerosol delivery system modality according to the invention; and
    [0111] [00111] Figure 2 shows a detailed view of a cartridge according to an embodiment of the invention without the outer housing.
    [0112] [00112] Figure 1 (a) shows an aerosol dispensing system 100 having approximately the same shape and size as a conventional smoking article, such as a cigar and a cigarette. The aerosol dispensing system 100 comprises a device 102, a cartridge 104 and a nozzle 106. The nozzle 106 is part of the cartridge 104. The cartridge 104 comprises air inlets 108 positioned upstream of the nozzle, and an air outlet 110 in the mouth end of the nozzle 106. A switch 112 is provided in the device.
    [0113] [00113] Figure 1 (b) shows a cross-sectional view of the aerosol dispensing system 100, in which further details of the device 102 and the cartridge 104 are shown. Cartridge 104 comprises a first compartment 114 comprising a pyruvic acid and a second compartment 116 comprising a liquid nicotine formulation. As shown in Figure 1 (b), the first compartment 114 is arranged circumferentially around the second compartment 116 and is defined by the outer circumferential surface of the second compartment 116 and the inner circumferential surface of the outer housing 118 of the cartridge 104.
    [0114] [00114] As shown in Figure 1 (c), the first compartment 114 comprises a porous µl of fibrous material 120 with pyruvic acid adsorbed thereon. The cartridge 104 further comprises a capillary wick 122 having a first end inside the second compartment 116 and a second end outside the second compartment. The capillary wick 122 is configured to transmit the liquid nicotine formulation from the second compartment 116 to the vaporizer surrounding the second end of the capillary wick 122. The vaporizer comprises an electric heater. An aerosol forming chamber 124 is provided downstream of the second compartment 116 in the nozzle 106. The nozzle 106 may comprise a third compartment (not shown) that comprises a filter material.
    [0115] [00115] Device 102 comprises a power source 126 in the form of a rechargeable battery. The device 102 further comprises electronic circuits 128 configured to control the supply of energy from the power source 126 to the vaporizer. The device 102 also comprises a heater (not shown) configured to heat the first compartment 114 of the cartridge 104.
    [0116] [00116] Figure 1 (c) shows the aerosol dispensing system 100 with its separate component parts. The aerosol dispensing system 100 is configured in such a way that the cartridge 104 is disposable, and as such, it can be separated from the device 102, and replaced. A coupling portion 130 is provided to allow cartridge 104 to be coupled to device 102. Coupling portion 130 comprises a male threaded portion on device 102 and a female threaded portion on cartridge 104. Coupling portion 130 also comprises electrical connectors (not shown) that allow energy to be supplied to the vaporizer. Figure 1 (d) shows an alternative view of the aerosol delivery system shown in Figure 1 (c).
    [0117] [00117] When in use, the user brings in the mouth end of the nozzle 106, so that the air is sucked into the inside of the cartridge 104 through the air intakes 108 in the external housing 118, downstream through the cartridge 104, and then out of the air outlet 110 at the nozzle 106 and into the user's mouth. The air enters the first compartment 114 and captures the vapor of the pyruvic acid passing over the porous µl of fibrous material 120 with ad-sorbed pyruvic acid within it. To allow consistent generation of pyruvic acid vapor, the first compartment is heated by the heater in the device to approximately 40 ° C. Alternatively, the heater can heat the air drawn into the cartridge 104 through the air inlets 108 in the outer housing 118 before it passes through the first compartment 114. The air flow that leaves the first compartment 114 and subsequently passes through the vaporizer is an air flow that contains pyruvic acid.
    [0118] [00118] Puff detection sensors (not shown) that communicate with electronic circuits 28 are provided. When a puff is detected, the electronic circuit activates the vaporizer to vaporize the liquid nicotine formulation. The air flow containing pyruvic acid and the vaporized nicotine formulation are drawn downstream into the aerosol-forming chamber 124. Pyruvic acid and nicotine interact in the gas phase in the aerosol-forming chamber 124 to form nicotine salt particles with a mass average aerodynamic particle diameter between about 0.5 microns and about 5 microns. The aerosolized nicotine salt particles are drawn out of the cartridge 104 and into the user's mouth via the air outlet 110 in the nozzle 106. The aerosol dispensing system 100 is configured to deliver about 100 micrograms of nicotine to the user by drag. The electronic circuit is configured to supply approximately 0.14 W of energy to the vaporizer for each drag.
    [0119] [00119] Any unreacted pyruvic acid can be removed from the aerosol of nicotine salt particles by the filtration material in the third compartment in the nozzle 106.
    [0120] [00120] The first compartment 116 is configured to store approximately 150 microliters of pyruvic acid, and the second compartment is configured to store approximately 100 microliters of the liquid nicotine formulation. Power source 126 is supplied with sufficient power to allow about 200 to 500 puffs before it is necessary to recharge it. The volume of the first and second compartments is sufficient to also allow 200 to 500 puffs before the cartridge needs to be replaced. Each puff releases approximately 100 micrograms of nicotine and approximately 60 micrograms of pyruvic acid. To optimize the interaction between nicotine and pyruvic acid, a molar ratio of approximately 1: 1 is preferred.
    [0121] [00121] Figure 2 shows a detailed view of a cartridge 200 comprising the first compartment and the second compartment; the configuration shown is an alternative to the alternative shown in Figures 1 (a) - (d). For the sake of simplicity, the outer housing of the cartridge has been omitted from Figure 2. Figure 2 also shows the route of air flow through the cartridge. As can be seen, the cartridge 200 comprises a first compartment 202 around a portion of the second compartment 116 circumferentially. The second end of the capillary wick 204 is circumscribed by an electric heater 206. The electric heater 206 is in the form of a elongated wire wound around capillary wick 204. Arrow 208 shows the airflow passage path from the air inlets to the first compartment 202, and over capillary wick 204. Electrical contacts 210 are provided to connect the electric heater 206 to the power source on the device (not shown). Example of nicotine batch heating
    [0122] [00122] To avoid nicotine losses between puffs and to simulate a puff detection system, a reference Health Canada smoke regime was applied (55 ml puff volume, 2 second puff duration, 30 second interval between puffs) and the PDSP pump signal was used to conduct the heating / vaporization of nicotine through a supply of food during the 2s puff.
    [0123] [00123] In the following experiment, an aerosol dispensing system shown in Figure 1b was prepared. A cartridge including a capillary wick and a heating wire was filled with pure nicotine, while a porous µl (XMF-0507 tank) saturated with 150 µl pyruvic acid was positioned upstream in the ingested air flow. Five smoke courses of 30 puffs were completed using increasing heating energy, from 0 to 0.2W. Distributions from groups of 30 puffs were collected on Cambridge filters and analyzed for pyruvic acid and nicotine. The results are shown in the table below:
    [0124] [00124] As the pyruvic acid µlug is not heated (maintained at a laboratory temperature of 22 ° C), pyruvic acid distributions are relatively constant, while nicotine distributions grow as a function of heating energy. In the configuration of the experiment, the ideal equimolar ratio is reached when the nicotine is heated between 0.1 w and 0.15 W.
    [0125] [00125] Experience confirms that the very low demand for heating energy (compared to conventional e-cigarettes) provides the desired amount of ingredients in the aerosol forming chamber for distribution to a consumer.
    权利要求:
    Claims (13)
    [0001]
    Cartridge (104), comprising: a first compartment (114), comprising a source of volatile distribution enhancing compound; a second compartment (116) comprising a source of medication; a vaporizer to heat the medicine; characterized by: the cartridge (104) further comprises a transfer element for transmitting the medicine from the second compartment (116) to the vaporizer, wherein the transfer element comprises a capillarity material for transmitting the medicine from the second compartment (116) to the vaporizer by means of capillary action and in which the capillary material is a capillary wick (122) with a first portion extending to the second compartment (116) and a second portion adjacent to the vaporizer.
    [0002]
    Cartridge (104) according to claim 1, characterized in that it additionally comprises an aerosol forming chamber (124) in fluid communication with the first compartment (114) and the second compartment (116).
    [0003]
    Cartridge (104) according to claim 2, characterized in that it additionally comprises an air inlet (108) upstream of the first compartment (114) and at least one air outlet (110) downstream of the forming chamber aerosol dispenser (124), with at least one air inlet (108) and at least one air outlet (110) arranged to define an air flow route that extends from at least one air inlet. air (108) to at least one air outlet (110) via the first compartment (114), the vaporizer and the aerosol forming chamber (124).
    [0004]
    Cartridge (104) according to any one of the preceding claims, characterized in that the second compartment (116) comprises a sorption element with the drug absorbed therein.
    [0005]
    Cartridge (104) according to any one of the preceding claims, characterized in that the medicament comprises pure nicotine, a nicotine solution or a liquid tobacco extract.
    [0006]
    Cartridge (104) according to any one of the preceding claims, characterized in that the first compartment (114) comprises a sorption element with the volatile distribution enhancing compound sorbed therein.
    [0007]
    Cartridge (104) according to any one of the preceding claims, characterized in that the volatile distribution enhancing compound comprises an acid selected from the group consisting of 3-methyl-2-oxovaleric acid, pyruvic acid, 2-acid -oxovaleric, 4-methyl-2-oxovaleric acid, 3-methyl-2-oxobutanoic acid, 2-oxo-octanoic acid and combinations thereof.
    [0008]
    Cartridge (104) according to any one of the preceding claims, characterized by the fact that the vaporizer comprises an electrically driven heater, the heater being connectable to an electricity supply.
    [0009]
    Aerosol dispensing system (100), characterized by the fact that it comprises: a device (102) in cooperation with a cartridge (104) according to any one of the claims.
    [0010]
    Aerosol dispensing system (100) according to claim 9, characterized in that the device (102) or the cartridge (104) additionally comprises a nozzle (106) in fluid communication with the aerosol forming chamber ( 124).
    [0011]
    Aerosol dispensing system (100) according to claim 9 or 10, characterized in that the device (102) is configured to receive the cartridge (104), wherein the device (102) comprises: an external housing; an energy source (126); temperature control means for controlling the temperature of the first compartment (114) of the cartridge (104); temperature control means for controlling the temperature of the vaporizer for heating a medicament; and electronic circuits configured to control energy for the temperature control means of the power source (126); and wherein the electronic circuit is configured to maintain the first compartment (114) of the cartridge (104) at a temperature between about 30 ° C and about 50 ° C.
    [0012]
    Aerosol dispensing system (100), according to claim 11, characterized by the fact that the electronic circuit is configured to maintain the medication temperature at a temperature between about 70 ° C and about 100 ° C.
    [0013]
    Method for delivering aerosolized particles containing medicine to a user, the method characterized by the fact that it comprises: controlling the temperature of a volatile distribution enhancing compound at between about 30 ° C and about 50 ° C to form a vapor containing distribution enhancing compound; heating the medicine to a temperature between about 70 ° C and about 100 ° C in order to form a vapor containing medicine; and placing the vapor containing distribution enhancing compound in contact with the medicine containing vapor in order to form aerosolized particles containing medicine.
    类似技术:
    公开号 | 公开日 | 专利标题
    BR112015026971B1|2021-02-17|cartridge, system and method of delivery to an electrically heated aerosol user containing medicine
    EP2967138B1|2017-11-22|Aerosol-generating system with differential heating
    RU2665190C2|2018-08-28|Aerosol-generating system comprising a delivery enhancing compound source and medicament source
    RU2665447C2|2018-08-29|Reusable aerosol generating system
    RU2670952C1|2018-10-25|Aerosol-generating system for generating and controlling quantity of nicotine salt particles
    RU2654192C1|2018-05-16|Aerosol generating system for the delivery of nicotine salt particles
    KR20180051486A|2018-05-16|A system for an aerosol-forming article comprising a cartridge and a cartridge
    US10485261B2|2019-11-26|Aerosol-generating system comprising a novel delivery enhancing compound source
    BR112016011058B1|2021-08-31|AEROSOL GENERATING SYSTEM TO GENERATE AND CONTROL THE AMOUNT OF NICOTINE SALT PARTICLES
    同族专利:
    公开号 | 公开日
    AU2014270532A1|2015-11-05|
    ZA201506730B|2017-03-29|
    JP2019162148A|2019-09-26|
    US20160081395A1|2016-03-24|
    UA120351C2|2019-11-25|
    HK1219843A1|2017-04-21|
    IL241544A|2021-01-31|
    KR20160008524A|2016-01-22|
    HUE052170T2|2021-04-28|
    ES2835401T3|2021-06-22|
    BR112015026971A2|2017-07-25|
    MX2015016075A|2016-03-21|
    EP2999365A2|2016-03-30|
    WO2014187770A2|2014-11-27|
    RU2015154108A|2017-06-26|
    JP2016519937A|2016-07-11|
    MY177775A|2020-09-23|
    EP2999365B1|2020-11-04|
    AU2014270532B2|2018-11-01|
    PL2999365T3|2021-04-19|
    AR096353A1|2015-12-23|
    JP6832701B2|2021-02-24|
    PH12015502016A1|2016-01-11|
    PH12015502016B1|2016-01-11|
    SG11201508686UA|2015-11-27|
    CA2910549A1|2014-11-27|
    RU2655188C2|2018-05-24|
    TW201505571A|2015-02-16|
    CN105407748A|2016-03-16|
    WO2014187770A3|2015-03-19|
    TWI697288B|2020-07-01|
    KR102278193B1|2021-07-19|
    US10721963B2|2020-07-28|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US5591368A|1991-03-11|1997-01-07|Philip Morris Incorporated|Heater for use in an electrical smoking system|
    US5505214A|1991-03-11|1996-04-09|Philip Morris Incorporated|Electrical smoking article and method for making same|
    US5498855A|1992-09-11|1996-03-12|Philip Morris Incorporated|Electrically powered ceramic composite heater|
    US5388594A|1991-03-11|1995-02-14|Philip Morris Incorporated|Electrical smoking system for delivering flavors and method for making same|
    US5514630A|1994-10-06|1996-05-07|Saint Gobain/Norton Industrial Ceramics Corp.|Composition for small ceramic igniters|
    DE19854005C2|1998-11-12|2001-05-17|Reemtsma H F & Ph|Inhalable aerosol delivery system|
    US6598607B2|2001-10-24|2003-07-29|Brown & Williamson Tobacco Corporation|Non-combustible smoking device and fuel element|
    WO2003095688A2|2002-05-09|2003-11-20|Harmonics, Inc|Tapecast electro-conductive cermets for high temperature resistive heating systems|
    CN2719043Y|2004-04-14|2005-08-24|韩力|Atomized electronic cigarette|
    ITME20050008A1|2005-12-09|2006-03-10|Brumil Internat Srl|SYSTEM THAT ALLOWS RELEASE OF NICOTINE FOR SUCTION, INTENDED FOR CIGARETTE SMOKERS.|
    WO2007078273A1|2005-12-22|2007-07-12|Augite Incorporation|No-tar electronic smoking utensils|
    CN201067079Y|2006-05-16|2008-06-04|韩力|Simulation aerosol inhaler|
    EP2708256A3|2007-03-30|2014-04-02|Philip Morris Products S.A.|Device and method for delivery of a medicament|
    CN100593982C|2007-09-07|2010-03-17|中国科学院理化技术研究所|Electronic cigarette having nanometer sized hyperfine space warming atomizing functions|
    EP2113178A1|2008-04-30|2009-11-04|Philip Morris Products S.A.|An electrically heated smoking system having a liquid storage portion|
    MY177136A|2009-03-17|2020-09-08|Philip Morris Products Sa|Tobacco-based nicotine aerosol generation system|
    CN101878958B|2009-07-14|2012-07-18|方晓林|Atomizer of electronic cigarette|
    CN101606758B|2009-07-14|2011-04-13|方晓林|Electronic cigarette|
    AU2010295883B2|2009-09-16|2015-08-20|Philip Morris Products Sa|Improved device and method for delivery of a medicament|
    EP2319334A1|2009-10-27|2011-05-11|Philip Morris Products S.A.|A smoking system having a liquid storage portion|
    DE102011111999B4|2011-08-31|2015-02-19|Rainer Krapf|Apparatus and method for producing drug-loaded aqueous aerosols|
    TWI546023B|2011-10-27|2016-08-21|菲利浦莫里斯製品股份有限公司|An electrically operated aerosol generating system having aerosol production control|US10244793B2|2005-07-19|2019-04-02|Juul Labs, Inc.|Devices for vaporization of a substance|
    US10279934B2|2013-03-15|2019-05-07|Juul Labs, Inc.|Fillable vaporizer cartridge and method of filling|
    US8820330B2|2011-10-28|2014-09-02|Evolv, Llc|Electronic vaporizer that simulates smoking with power control|
    US10517530B2|2012-08-28|2019-12-31|Juul Labs, Inc.|Methods and devices for delivering and monitoring of tobacco, nicotine, or other substances|
    US10034988B2|2012-11-28|2018-07-31|Fontem Holdings I B.V.|Methods and devices for compound delivery|
    JP6400678B2|2013-05-06|2018-10-03|ジュール・ラブズ・インコーポレイテッドＪｕｕｌ Ｌａｂｓ， Ｉｎｃ．|Nicotine salt formulation for aerosol device and method thereof|
    CN105473012B|2013-06-14|2020-06-19|尤尔实验室有限公司|Multiple heating elements with individual vaporizable materials in electronic vaporization devices|
    EA033402B1|2013-07-19|2019-10-31|Altria Client Services Llc|Liquid aerosol formulation of an electronic smoking article|
    WO2015042412A1|2013-09-20|2015-03-26|E-Nicotine Technology. Inc.|Devices and methods for modifying delivery devices|
    US10039321B2|2013-11-12|2018-08-07|Vmr Products Llc|Vaporizer|
    US10463069B2|2013-12-05|2019-11-05|Juul Labs, Inc.|Nicotine liquid formulations for aerosol devices and methods thereof|
    US10058129B2|2013-12-23|2018-08-28|Juul Labs, Inc.|Vaporization device systems and methods|
    US10512282B2|2014-12-05|2019-12-24|Juul Labs, Inc.|Calibrated dose control|
    US9549573B2|2013-12-23|2017-01-24|Pax Labs, Inc.|Vaporization device systems and methods|
    HUE053511T2|2013-12-23|2021-07-28|Juul Labs Int Inc|Vaporization device systems|
    US10076139B2|2013-12-23|2018-09-18|Juul Labs, Inc.|Vaporizer apparatus|
    US20160366947A1|2013-12-23|2016-12-22|James Monsees|Vaporizer apparatus|
    US10159282B2|2013-12-23|2018-12-25|Juul Labs, Inc.|Cartridge for use with a vaporizer device|
    EP3138425A1|2014-06-27|2017-03-08|Fontem Holdings 1 B.V.|Electronic smoking device and capsule system|
    US9700082B2|2014-09-16|2017-07-11|Nike, Inc.|Wrap front bra|
    HUE045363T2|2014-11-17|2019-12-30|Mcneil Ab|Electronic nicotine delivery system|
    JP6710684B2|2014-11-17|2020-06-17|マクニール アーベーＭｃｎｅｉｌ Ａｂ|Disposable cartridge for use in electronic nicotine delivery system|
    PL3247235T3|2015-01-22|2021-04-06|Fontem Holdings 1 B.V.|Electronic vaporization devices|
    GB201501950D0|2015-02-05|2015-03-25|Jt Int Sa|Aerosol guiding device and aerosol generating system comprising said aerosol guiding device|
    GB201501951D0|2015-02-05|2015-03-25|Jt Int Sa|Aerosol guiding device and aerosol generating system comprising said aerosol guiding device|
    WO2016156212A1|2015-03-27|2016-10-06|Philip Morris Products S.A.|Aerosol-generating system comprising integrated piercing element|
    RU2692811C2|2015-03-27|2019-06-27|Филип Моррис Продактс С.А.|Aerosol-forming system comprising a bimetallic strip|
    JP6878294B2|2015-03-27|2021-05-26|フィリップ・モーリス・プロダクツ・ソシエテ・アノニム|Aerosol generation system with ruptured area|
    CA2978372A1|2015-03-27|2016-10-06|Philip Morris Products S.A.|Aerosol-generating system comprising a resilient member|
    CN107427077B|2015-03-27|2021-02-02|菲利普莫里斯生产公司|Resealable aerosol-generating article|
    EA036219B1|2015-05-01|2020-10-15|Джапан Тобакко Инк.|Non-burning type flavor inhaler and atomizing unit|
    EP3283149A1|2015-06-10|2018-02-21|Evolv, LLC|Electronic vaporizer having reduced particle size|
    US10362803B2|2015-06-10|2019-07-30|Evolv, Llc|Electronic vaporizer having reduced particle size|
    UA123052C2|2015-06-26|2021-02-10|Брітіш Амерікан ТобаккоЛімітед|Apparatus for heating smokable material|
    USD843052S1|2015-09-21|2019-03-12|British American TobaccoLimited|Aerosol generator|
    EP3393283B1|2015-12-22|2020-02-05|Philip Morris Products S.a.s.|A cartridge for an aerosol-generating system and an aerosol-generating system comprising a cartridge|
    EP3183980B1|2015-12-22|2018-08-08|Philip Morris Products S.a.s.|A cartridge for an aerosol-generating system and an aerosol-generating system comprising a cartridge|
    MX2018007311A|2015-12-22|2018-09-11|Philip Morris Products Sa|A cartridge for an aerosol-generating system and an aerosol-generating system comprising a cartridge.|
    PT3183979T|2015-12-22|2018-10-15|Philip Morris Products Sa|Cartridge for an aerosol-generating system and an aerosol-generating system comprising a cartridge|
    US10092036B2|2015-12-28|2018-10-09|Rai Strategic Holdings, Inc.|Aerosol delivery device including a housing and a coupler|
    DE202017007467U1|2016-02-11|2021-12-08|Juul Labs, Inc.|Fillable vaporizer cartridge|
    SG11201806801VA|2016-02-11|2018-09-27|Juul Labs Inc|Securely attaching cartridges for vaporizer devices|
    US10433580B2|2016-03-03|2019-10-08|Altria Client Services Llc|Methods to add menthol, botanic materials, and/or non-botanic materials to a cartridge, and/or an electronic vaping device including the cartridge|
    US10455863B2|2016-03-03|2019-10-29|Altria Client Services Llc|Cartridge for electronic vaping device|
    US10368580B2|2016-03-08|2019-08-06|Altria Client Services Llc|Combined cartridge for electronic vaping device|
    US10405582B2|2016-03-10|2019-09-10|Pax Labs, Inc.|Vaporization device with lip sensing|
    US20170258140A1|2016-03-11|2017-09-14|Altria Client Services Llc|Multiple dispersion generator e-vaping device|
    US10368581B2|2016-03-11|2019-08-06|Altria Client Services Llc|Multiple dispersion generator e-vaping device|
    US10357060B2|2016-03-11|2019-07-23|Altria Client Services Llc|E-vaping device cartridge holder|
    US10463076B2|2016-04-11|2019-11-05|Altria Client Services Llc|Electronic vaping device|
    EP3448185A1|2016-04-28|2019-03-06|Philip Morris Products S.a.s.|Cartridge comprising a coupling element for use in an aerosol-generating system|
    RU2709485C1|2016-05-13|2019-12-18|Бритиш Америкэн ТобэккоЛимитед|Device for smoking material heating and method of heater formation|
    TW201742554A|2016-05-13|2017-12-16|英美煙草（投資）有限公司|Apparatus for receiving smokable material|
    TW201742556A|2016-05-13|2017-12-16|British American Tobacco Investments Ltd|Apparatus for heating smokable material|
    US20180071274A1|2016-06-06|2018-03-15|Nicholas A. Havercroft|Medical product for reducing and/or eliminating symptoms of nicotine withdrawal|
    US20170348495A1|2016-06-06|2017-12-07|Nicholas A. Havercroft|Modified nebulizer, method and system for delivering pharmaceutical products to an individual|
    USD849996S1|2016-06-16|2019-05-28|Pax Labs, Inc.|Vaporizer cartridge|
    USD836541S1|2016-06-23|2018-12-25|Pax Labs, Inc.|Charging device|
    USD851830S1|2016-06-23|2019-06-18|Pax Labs, Inc.|Combined vaporizer tamp and pick tool|
    USD848057S1|2016-06-23|2019-05-07|Pax Labs, Inc.|Lid for a vaporizer|
    GB201612945D0|2016-07-26|2016-09-07|British American TobaccoLtd|Method of generating aerosol|
    USD842536S1|2016-07-28|2019-03-05|Juul Labs, Inc.|Vaporizer cartridge|
    USD825102S1|2016-07-28|2018-08-07|Juul Labs, Inc.|Vaporizer device with cartridge|
    WO2018069995A1|2016-10-12|2018-04-19|日本たばこ産業株式会社|Flavor inhaler|
    JP2019535301A|2016-11-30|2019-12-12|フィリップ・モーリス・プロダクツ・ソシエテ・アノニム|Aerosol generation system having an outer housing|
    US10015991B1|2016-12-29|2018-07-10|Altria Client Services Llc|Hybrid E-vaping cartridge, E-vaping device including a hybrid E-vaping cartridge, and method of making thereof|
    US11129413B2|2017-03-13|2021-09-28|Altria Client Services Llc|Three-piece electronic vaping device with planar heater|
    EP3599906B1|2017-03-29|2021-05-19|Philip Morris Products S.A.|Cartridge assembly comprising a blocking element|
    KR102216139B1|2017-04-28|2021-02-16|주식회사 케이티앤지|Method and apparatus for generating aerosols|
    WO2018199504A1|2017-04-28|2018-11-01|주식회사 케이티앤지|Aerosol generation method and apparatus|
    CN111163820A|2017-08-09|2020-05-15|二十六药业有限公司|Pulmonary delivery device|
    USD887632S1|2017-09-14|2020-06-16|Pax Labs, Inc.|Vaporizer cartridge|
    KR20190093024A|2018-01-31|2019-08-08|주식회사 케이티앤지|An apparatus for generating aerosols|
    US20200035118A1|2018-07-27|2020-01-30|Joseph Pandolfino|Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes|
    US10897925B2|2018-07-27|2021-01-26|Joseph Pandolfino|Articles and formulations for smoking products and vaporizers|
    GB201814198D0|2018-08-31|2018-10-17|Nicoventures Trading Ltd|Apparatus for an aerosol generating device|
    USD928393S1|2018-10-15|2021-08-17|Nicoventures Trading Limited|Aerosol generator|
    USD924472S1|2018-10-15|2021-07-06|Nicoventures Trading Limited|Aerosol generator|
    US11071326B2|2018-11-20|2021-07-27|Altria Client Services Llc|E-vaping device|
    US20200154783A1|2018-11-20|2020-05-21|Altria Client Services Llc|Vaporizer assembly and/or components thereof|
    USD943166S1|2019-07-30|2022-02-08|Nicoventures Trading Limited|Accessory for aerosol generator|
    USD926367S1|2020-01-30|2021-07-27|Nicoventures Trading Limited|Accessory for aerosol generator|
    US11235110B1|2020-07-29|2022-02-01|Gregory Ellis|Delivery system for ayahuasca-like substances|
    法律状态:
    2018-11-06| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|
    2020-02-11| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|
    2020-12-29| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|
    2021-02-17| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/05/2014, OBSERVADAS AS CONDICOES LEGAIS. |
    优先权:
    申请号 | 申请日 | 专利标题
    EP13168609|2013-05-21|
    EP13168609.9|2013-05-21|
    PCT/EP2014/060225|WO2014187770A2|2013-05-21|2014-05-19|Electrically heated aerosol delivery system|
    [返回顶部]